Pembrolizumab 400 mg every 6 weeks as first-line therapy for advanced melanoma (KEYNOTE-555): Results from cohort B of an open-label, phase 1 study.
Saved in:
| Title: | Pembrolizumab 400 mg every 6 weeks as first-line therapy for advanced melanoma (KEYNOTE-555): Results from cohort B of an open-label, phase 1 study. |
|---|---|
| Authors: | Cohen G; Mary Potter Oncology Centre, Pretoria, South Africa., Rapoport B; The Medical Oncology Centre of Rosebank, Johannesburg, South Africa.; Department of Immunology, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa., Chan SW; Sandton Oncology, Johannesburg, South Africa., Ruff P; University of Witwatersrand Faculty of Health Sciences, Johannesburg, South Africa., Arance A; Hospital Clínic de Barcelona, Barcelona, Spain., Mujika Eizmendi K; Onkologikoa Donostia, San Sebastian, Spain., Houghton B; Port Macquarie Base Hospital, Port Macquarie, New South Wales, Australia., Brown MP; Cancer Clinical Trials Unit, Royal Adelaide Hospital, and School of Medicine, The University of Adelaide, Adelaide, South Australia, Australia., Zielinski RM; Central West Cancer Care Centre, Orange Hospital, Orange, New South Wales, Australia.; Western Sydney University, Sydney, New South Wales, Australia., Muñoz Couselo E; Department of Medical Oncology, Melanoma and Other Skin Cancers Unit, Vall d'Hebron University Hospital, Barcelona, Spain., Lyle M; Liz Plummer Cancer Care Centre, Cairns, Queensland, Australia., Anderson JR; Merck & Co., Inc., Rahway, New Jersey, United States of America., Jain L; Merck & Co., Inc., Rahway, New Jersey, United States of America., de Alwis D; Merck & Co., Inc., Rahway, New Jersey, United States of America., Lala M; Merck & Co., Inc., Rahway, New Jersey, United States of America., Akala O; Merck & Co., Inc., Rahway, New Jersey, United States of America., Chartash E; Merck & Co., Inc., Rahway, New Jersey, United States of America., Jacobs C; Cancer Care: Clinical & Radiation Oncology, Cape Town, South Africa. |
| Source: | PloS one [PLoS One] 2024 Nov 12; Vol. 19 (11), pp. e0309778. Date of Electronic Publication: 2024 Nov 12 (Print Publication: 2024). |
| Publication Type: | Journal Article; Clinical Trial, Phase I; Multicenter Study |
| Journal Info: | Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
